The global palmoplantar pustulosis (PPP) Market is witnessing significant growth due to the increasing prevalence of this chronic dermatological condition. PPP primarily affects the palms and soles, causing pustules and erythema, and is often associated with other conditions such as psoriasis. Epidemiological studies indicate that PPP affects approximately 0.05% to 0.1% of the global population, with a higher incidence in individuals aged 40 to 60 years. The condition is more common in women, with a female-to-male ratio of 3:1. Additionally, PPP is prevalent in regions with higher rates of autoimmune diseases, particularly in Europe and North America. The increasing awareness of PPP and advancements in biologic therapies are driving the demand for effective treatment options. Given the chronic and relapsing nature of the disease, patients often require long-term management, further expanding the treatment market. The rise in clinical research and the development of targeted therapies, including biologics, are key factors contributing to the market's growth trajectory.
